(2003020518)

11/04/03

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

162162

(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/30320 A3

(51) International Patent Classification[7]: A61K 35/28, 38/09, 31/56, A61P 37/04

(21) International Application Number: PCT/IB01/02350

(22) International Filing Date: 12 October 2001 (12.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PR 0745	13 October 2000 (13.10.2000)	AU
09/795,286	13 October 2000 (13.10.2000)	US
09/795,302	13 October 2000 (13.10.2000)	US
09/755,965	5 January 2001 (05.01.2001)	US
09/965,394	26 September 2001 (26.09.2001)	US

(71) Applicant and
(72) Inventor: BOYD, Richard [AU/AU]; Department of Pathology & Immunology, Monash Medical School, Commercial Road, Prahran, Victoria 3181 (AU).

(74) Agent: HUGHES, E., John, L.; Davies Collison Cave, Level 3, 303 Coronation Drive, Milton, QLD 4064 (AU).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

Published:
--- *with international search report*
- - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
20 June 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ACTION

(54) Title: STIMULATION OF THYMUS FOR VACCINATION DEVELOPMENT

(57) Abstract: The present disclosure provides methods for enhancing the response of a patient's immune system to vaccination. This is accomplished by reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are deliverd to increase the speed of regeneration of the patient's immune system. In a preferred embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In a preferred embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.

WO 02/30320 A3